title: Everolimus- and temsirolimus-associated enteritis: report of three cases.
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: Kavitha
authors.initials: K
authors.lastname: Parithivel
authors.forename: Nikhil
authors.initials: N
authors.lastname: Ramaiya
authors.forename: Jyothi Priya
authors.initials: JP
authors.lastname: Jagannathan
authors.forename: Kevin
authors.initials: K
authors.lastname: O'Regan
authors.forename: Katherine
authors.initials: K
authors.lastname: Krajewski
authors.forename: David
authors.initials: D
authors.lastname: Fisher
authors.forename: Toni K
authors.initials: TK
authors.lastname: Choueiri
authors.forename: Eric
authors.initials: E
authors.lastname: Jacobsen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D004751:Enteritis / Q000139:chemically induced*; D000068338:Everolimus; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000502:physiology
chemical_list: C401859:temsirolimus; D000068338:Everolimus; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus